Welcome to our dedicated page for AKRX news (Ticker: AKRX), a resource for investors and traders seeking the latest updates and insights on AKRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AKRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AKRX's position in the market.
Akorn Operating Company LLC received FDA approval for the first generic version of Cetrorelix Acetate for Injection, 0.25 mg, a bioequivalent to Merck Serono's Cetrotide®. This approval supports fertility treatments, offering a competitively priced option. Akorn has also gained Competitive Generic Therapy (CGT) designation, providing 180 days of market exclusivity starting from the commercial launch. U.S. sales for Cetrorelix were around $63 million through June 2022, with projections of $127 million for the full year.
